U
ARCA biopharma, Inc.
ABIO
NASDAQ
D
Sell
4/11/2024Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D- from E+ on 4/11/2024 due to an increase in the volatility index and solvency index. The quick ratio increased from 38.8 to 58.76.
ARCA biopharma, Inc. (ABIO) was upgraded to D- from E+ on 4/11/2024 due to an increase in the volatility index and solvency index. The quick ratio increased from 38.8 to 58.76.
E
Sell
3/14/2023Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index, volatility index and valuation index.
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index, volatility index and valuation index.
D
Sell
2/9/2023Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index and volatility index.
ARCA biopharma, Inc. (ABIO) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index and volatility index.
E
Sell
2/8/2023Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and valuation index.
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and valuation index.
D
Sell
5/16/2022Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index and volatility index.
ARCA biopharma, Inc. (ABIO) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index and volatility index.
E
Sell
5/13/2022Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D on 05/13/2022.
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D on 05/13/2022.
D
Sell
5/4/2022Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D from E+ on 5/4/2022 due to an increase in the growth index, total return index and volatility index. EBIT increased 42.31% from -$5.68M to -$3.28M, earnings per share increased from -$0.3937 to -$0.23, and operating cash flow increased 13.12% from -$4.95M to -$4.3M.
ARCA biopharma, Inc. (ABIO) was upgraded to D from E+ on 5/4/2022 due to an increase in the growth index, total return index and volatility index. EBIT increased 42.31% from -$5.68M to -$3.28M, earnings per share increased from -$0.3937 to -$0.23, and operating cash flow increased 13.12% from -$4.95M to -$4.3M.
E
Sell
4/20/2022Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D- on 04/20/2022.
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D- on 04/20/2022.
D
Sell
3/21/2022Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to D- from D on 3/21/2022 due to a decline in the growth index, total return index and volatility index. EBIT declined 20.44% from -$4.72M to -$5.68M, earnings per share declined from -$0.327 to -$0.3937, and operating cash flow declined 1.58% from -$4.87M to -$4.95M.
ARCA biopharma, Inc. (ABIO) was downgraded to D- from D on 3/21/2022 due to a decline in the growth index, total return index and volatility index. EBIT declined 20.44% from -$4.72M to -$5.68M, earnings per share declined from -$0.327 to -$0.3937, and operating cash flow declined 1.58% from -$4.87M to -$4.95M.
D
Sell
11/23/2021Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D from D- on 11/23/2021.
ARCA biopharma, Inc. (ABIO) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index, solvency index and volatility index.
ARCA biopharma, Inc. (ABIO) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index, solvency index and volatility index.
D
Sell
4/19/2021Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D from D- on 4/19/2021 due to an increase in the total return index.
ARCA biopharma, Inc. (ABIO) was upgraded to D from D- on 4/19/2021 due to an increase in the total return index.
D
Sell
3/19/2021Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to D- from D on 3/19/2021 due to a large decline in the growth index and valuation index. EBIT declined 157.59% from -$1.99M to -$5.13M, earnings per share declined from -$0.3294 to -$0.5466, and operating cash flow declined 49.6% from -$2M to -$3M.
ARCA biopharma, Inc. (ABIO) was downgraded to D- from D on 3/19/2021 due to a large decline in the growth index and valuation index. EBIT declined 157.59% from -$1.99M to -$5.13M, earnings per share declined from -$0.3294 to -$0.5466, and operating cash flow declined 49.6% from -$2M to -$3M.
D
Sell
5/1/2020Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index, solvency index and total return index. The quick ratio increased from 8.39 to 9.03.
ARCA biopharma, Inc. (ABIO) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index, solvency index and total return index. The quick ratio increased from 8.39 to 9.03.
D
Sell
4/18/2019Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D- from E+ on 4/18/2019 due to an increase in the valuation index, volatility index and total return index.
ARCA biopharma, Inc. (ABIO) was upgraded to D- from E+ on 4/18/2019 due to an increase in the valuation index, volatility index and total return index.
E
Sell
4/3/2019Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D- on 4/3/2019 due to a decline in the valuation index and total return index.
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D- on 4/3/2019 due to a decline in the valuation index and total return index.
D
Sell
1/28/2019Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D- from E+ on 1/28/2019 due to an increase in the total return index and efficiency index. Net income increased 24.72% from -$2.12M to -$1.59M.
ARCA biopharma, Inc. (ABIO) was upgraded to D- from E+ on 1/28/2019 due to an increase in the total return index and efficiency index. Net income increased 24.72% from -$2.12M to -$1.59M.
E
Sell
5/24/2018Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D- on 5/24/2018 due to a decline in the total return index and volatility index.
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D- on 5/24/2018 due to a decline in the total return index and volatility index.
D
Sell
12/22/2017Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D- from E+ on 12/22/2017 due to a noticeable increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.5922 to -$0.3854, operating cash flow increased 19.85% from -$4.96M to -$3.97M, and EBIT increased 19.5% from -$5.56M to -$4.48M.
ARCA biopharma, Inc. (ABIO) was upgraded to D- from E+ on 12/22/2017 due to a noticeable increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.5922 to -$0.3854, operating cash flow increased 19.85% from -$4.96M to -$3.97M, and EBIT increased 19.5% from -$5.56M to -$4.48M.
E
Sell
7/31/2017Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D- on 7/31/2017 due to a decline in the volatility index.
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D- on 7/31/2017 due to a decline in the volatility index.
D
Sell
7/13/2017Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D- from E+ on 7/13/2017 due to an increase in the total return index and volatility index.
ARCA biopharma, Inc. (ABIO) was upgraded to D- from E+ on 7/13/2017 due to an increase in the total return index and volatility index.
E
Sell
6/2/2017Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D- on 6/2/2017 due to a noticeable decline in the growth index, solvency index and efficiency index. Total capital declined 18.73% from $22.19M to $18.04M, the quick ratio declined from 8.83 to 7.63, and operating cash flow declined 13.07% from -$3.84M to -$4.34M.
ARCA biopharma, Inc. (ABIO) was downgraded to E+ from D- on 6/2/2017 due to a noticeable decline in the growth index, solvency index and efficiency index. Total capital declined 18.73% from $22.19M to $18.04M, the quick ratio declined from 8.83 to 7.63, and operating cash flow declined 13.07% from -$3.84M to -$4.34M.
D
Sell
3/18/2016Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to D- from D on 3/18/2016 due to a decline in the growth index, efficiency index and solvency index. The quick ratio declined from 31.81 to 25.8, EBIT declined 12.71% from -$2.82M to -$3.18M, and net income declined 12.58% from -$2.81M to -$3.17M.
ARCA biopharma, Inc. (ABIO) was downgraded to D- from D on 3/18/2016 due to a decline in the growth index, efficiency index and solvency index. The quick ratio declined from 31.81 to 25.8, EBIT declined 12.71% from -$2.82M to -$3.18M, and net income declined 12.58% from -$2.81M to -$3.17M.
D
Sell
3/11/2016Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to D from D+ on 3/11/2016 due to a major decline in the volatility index, total return index and efficiency index. Total capital declined 6.09% from $43.76M to $41.09M, and net income declined 3.49% from -$2.72M to -$2.81M.
ARCA biopharma, Inc. (ABIO) was downgraded to D from D+ on 3/11/2016 due to a major decline in the volatility index, total return index and efficiency index. Total capital declined 6.09% from $43.76M to $41.09M, and net income declined 3.49% from -$2.72M to -$2.81M.
D
Sell
9/18/2015Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D+ from D on 9/18/2015 due to an increase in the valuation index.
ARCA biopharma, Inc. (ABIO) was upgraded to D+ from D on 9/18/2015 due to an increase in the valuation index.
D
Sell
9/3/2015Downgrade
ARCA biopharma, Inc. (ABIO) was downgraded to D from D+ on 9/3/2015 due to a decline in the valuation index and total return index.
ARCA biopharma, Inc. (ABIO) was downgraded to D from D+ on 9/3/2015 due to a decline in the valuation index and total return index.
D
Sell
8/17/2015Upgraded
ARCA biopharma, Inc. (ABIO) was upgraded to D+ from D on 8/17/2015 due to an increase in the efficiency index, valuation index and solvency index. Total capital increased 260.83% from $12.13M to $43.76M, and the quick ratio increased from 10.75 to 32.51.
ARCA biopharma, Inc. (ABIO) was upgraded to D+ from D on 8/17/2015 due to an increase in the efficiency index, valuation index and solvency index. Total capital increased 260.83% from $12.13M to $43.76M, and the quick ratio increased from 10.75 to 32.51.
